<DOC>
	<DOCNO>NCT01681940</DOCNO>
	<brief_summary>The overall objective evaluate long-term efficacy , safety tolerability repeat Lamazym i.v . treatment patient 5-21 year age alpha-Mannosidosis</brief_summary>
	<brief_title>Long-term Efficacy Safety Lamazym Treatment Patients With Alpha-Mannosidosis</brief_title>
	<detailed_description />
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>The subject must participate phase 1 trial ( EudraCT number : 201002208436 ) phase 2a trial ( EudraCT number : 201002208526 ) Subject subject legally authorize guardian ( ) must provide sign , inform consent prior perform trialrelated activity ( trialrelated activity procedure would perform normal management subject ) The subject his/her guardian ( ) must ability comply protocol The subject walk without support Presence know chromosomal abnormality syndrome affect psychomotor development , alphaMannosidosis History bone marrow transplantation Presence know clinically significant cardiovascular , hepatic , pulmonary renal disease medical condition , opinion Investigator , would preclude participation trial Any medical condition serious intercurrent illness , extenuate circumstance , opinion investigator , would preclude participation trial . Pregnancy : Before start treatment investigator decide whether need contraception . This assessment do interview patient parent . The evaluation do continuously study Psychosis within last 3 month Planned major surgery , opinion investigator , would preclude participation trial Participation interventional trial test IMP except study Lamazym</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>